EXAS Stock Risk & Deep Value Analysis
Exact Sciences Corp
Healthcare • Diagnostics & Research
DVR Score
out of 10
The Bottom Line on EXAS
We analyzed Exact Sciences Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran EXAS through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Here's what we found.
📈EXAS Performance Overview3yr weekly
Unlock EXAS Performance Chart
See 3 years of price history, quarterly revenue trends, and DVR score changes
Weekly adjusted close · Quarterly revenue & EPS · DVR score history
EXAS Stock Risk Analysis
Overall Risk
Aggressive
Financial Risk
Medium
Market Risk
Medium
About Exact Sciences Corp (EXAS)
Sector
Healthcare
Industry
Diagnostics & Research
Market Cap Category
large
Market Cap
$16.11B
EXAS Deep Value Analysis
Compare EXAS to Similar Stocks
See how Exact Sciences Corp stacks up against related companies in our head-to-head analysis.
EXAS Red Flags & Warning Signs
Premium- ⚠
Negative or inconclusive results from ongoing MCED clinical trials
- ⚠
Increased competitive pressure or new market entrants in colorectal cancer screening
- ⚠
Slower-than-anticipated regulatory approvals or reimbursement decisions for new tests
- ⚠
Broader economic downturn impacting healthcare spending
Unlock EXAS Red Flags & Risk Warnings
Premium members see every risk event we found.
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
Unlock everything for $47/yr
$79/yrSave 41%
- ✓ Catalysts, bull case, moat & red flags
- ✓ Unlimited stock analyses + alerts
- ✓ Full database, search & portfolio (50 stocks)
7-day money back · Cancel anytime
EXAS Financial Health Metrics
Market Cap
$16.11B
EXAS Competitive Moat Analysis
PremiumMoat Rating
Narrow
Moat Trend
Expanding
Moat Sources
4 Identified
Cologuard's moat is durable due to extensive clinical data, established reimbursement, and high physician adoption rates, creating significant switching costs for healthcare providers. The emerging moat for MCED relies on proprietary technology, clinical validation, and the ability to scale rapidly, which is still developing.
EXAS Competitive Moat Analysis
Premium unlocks moat rating, sources & durability.
EXAS Catalysts & Growth Drivers
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated Feb 2026)
- •Updates on Cologuard 2.0 (next-gen) development and commercialization plan
- •Expansion of OncoExTra pan-cancer therapy selection test
Medium-Term (6-18 months)
- •Further clinical data readouts from BLUE-C study for MCED
- •Potential FDA submission for a specific multi-cancer early detection test or next-generation Cologuard
- •Progress on reimbursement coverage for new diagnostic tests
Long-Term (18+ months)
- •Broad commercialization and widespread adoption of the MCED platform
- •Significant international market expansion for core products and MCED
- •Diversification of the cancer diagnostics pipeline beyond current offerings
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
EXAS Bull Case: What Could Go Right
- ✓
Positive clinical trial readouts and accelerated regulatory pathways for MCED candidates (e.g., BLUE-C study data, FDA approvals)
- ✓
Increased Cologuard test volumes and expanding market penetration (especially in new age groups or geographies)
- ✓
Significant improvements in gross margins and progression towards sustainable profitability for the overall business
- ✓
Competitive landscape shifts, particularly any major advancements or setbacks for key MCED rivals
Bull Case Analysis
See what could go right with Premium
Never miss a move on EXAS
Create a free account to set price alerts and get notified on Telegram when EXAS hits your targets.
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential.
FAQ
What is the DVR Score for Exact Sciences Corp (EXAS)?
As of January 21, 2026, Exact Sciences Corp has a DVR Score of 5.2 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Exact Sciences Corp?
Exact Sciences Corp's market capitalization is approximately $16.1B. The company operates in the Healthcare sector within the Diagnostics & Research industry.
What ticker symbol does Exact Sciences Corp use?
EXAS is the ticker symbol for Exact Sciences Corp. The company trades on the NCM.
What is the risk level for EXAS stock?
Our analysis rates Exact Sciences Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
How often is the EXAS DVR analysis updated?
Our AI-powered analysis of Exact Sciences Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on January 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research and consult with a qualified financial advisor.